Winston Pharmaceuticals, Inc.
WPHM · OTC
3/31/2010 | 12/31/2009 | 9/30/2009 | 6/30/2009 | |
|---|---|---|---|---|
| Revenue | $317 | $339 | $351 | $365 |
| % Growth | -6.6% | -3.3% | -4% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $317 | $339 | $351 | $365 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $326 | $346 | $583 | $588 |
| G&A Expenses | $450 | $553 | $468 | $463 |
| SG&A Expenses | $450 | $553 | $468 | $463 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $2 | $2 | $2 | $2 |
| Operating Expenses | $778 | $901 | $1,053 | $1,053 |
| Operating Income | -$462 | -$562 | -$703 | -$688 |
| % Margin | -145.7% | -165.8% | -200.5% | -188.4% |
| Other Income/Exp. Net | $1 | $0 | $0 | $76 |
| Pre-Tax Income | -$461 | -$562 | -$702 | -$612 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$461 | -$562 | -$702 | -$612 |
| % Margin | -145.5% | -165.7% | -200.4% | -167.7% |
| EPS | -0.01 | 0 | -0.01 | -0.01 |
| % Growth | – | 100% | 0% | – |
| EPS Diluted | -0.01 | 0 | -0.01 | -0.01 |
| Weighted Avg Shares Out | 77,409 | 0 | 56,686 | 55,443 |
| Weighted Avg Shares Out Dil | 77,409 | 0 | 56,686 | 55,443 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $2 | $2 | $2 | $2 |
| EBITDA | -$459 | -$560 | -$701 | -$685 |
| % Margin | -145.1% | -165.2% | -199.9% | -187.8% |